wire - news in brief

« BACK

Medicine/Pharmacology



Results 1 - 50 of 1031.
1 2 3 4 5 ... 21 Next »

Medicine/Pharmacology - Life Sciences
18.01.2017
Unveiling the biology behind nonalcoholic fatty liver disease
Unveiling the biology behind nonalcoholic fatty liver disease
EPFL scientists have discovered a new biological mechanism behind nonalcoholic fatty liver disease. Nonalcoholic fatty liver disease covers a range of diseases that result from fat accumulation in the liver, but not as a result of alcohol abuse. Fat buildup can lead to liver inflammation, scarring and irreversible damage, such as cirrhosis and liver failure.
Medicine/Pharmacology - Life Sciences
17.01.2017
On track to heal leukaemia
On track to heal leukaemia
Media releases, information for representatives of the media Media Relations (E) The first clinical studies for a new type of immunotherapy for leukaemia are beginning at Bern's University Hospital and the Department of Clinical Research (DCR) of the University of Bern. Antibodies discovered in the laboratory should inhibit the growth of tumour cells.
Medicine/Pharmacology - Life Sciences
09.01.2017
New insights into mechanisms of breast cancer development and resistance to therapy
Why does breast cancer develop and how come certain patients are resistant to established therapies' Researchers from the University of Basel have gained new insights into the molecular processes in breast tissue. They identified the tumor suppressor LATS as a key player in the development and treatment of breast cancer.
Life Sciences - Medicine/Pharmacology
06.01.2017
Medicine/Pharmacology - Life Sciences
06.01.2017
Novartis invests in next generation therapies to reduce cardiovascular risk in patients with underlying lipid disorders
Novartis enters into an exclusive option agreement with Ionis and Akcea to license two investigational treatments expected to significantly reduce cardiovascular risk in patients living with elevated
Life Sciences - Medicine/Pharmacology
06.01.2017
Autoimmunity and Infections: When the Body Fights Itself
Basel-based doctors are on the trail of a possible connection between autoimmune diseases and infections: errors can occur when immune cells absorb certain proteins from pathogen cells. These It is already known that there is a connection between infections and autoimmunity – the inability of an organism to recognize parts of its own body as “self”.
Medicine/Pharmacology - Physics/Materials Science
03.01.2017
Looking back at 2016 (2/2)
Looking back at 2016 (2/2)
Slowing the aging process, improving data security, enabling paraplegics to walk again, transporting vaccines at room temperature to warm countries, creating jobs with the CHF 400 million raised by spin-offs - those are just some of the many areas where EPFL scientists have made a lasting contribution.
Life Sciences - Medicine/Pharmacology
27.12.2016
Looking back at 2016 (1/2)
Looking back at 2016 (1/2)
Health, energy, maths and chocolate: no field of research has been neglected last year by EPFL's scientists.  Cheaper solar cells with 20.2% efficiency Some of the most promising solar cells today use light-harvesting films made from perovskites. However, perovskite-based solar cells use expensive ‘hole-transporting' materials, whose function is to move the positive charges that are generated when light hits the perovskite film.
Medicine/Pharmacology - Life Sciences
23.12.2016
Treating cancer with drugs for diabetes and hypertension
Treating cancer with drugs for diabetes and hypertension
A combination of a diabetes medication and an antihypertensive drug can effectively combat cancer cells. The team of researchers led by Prof. Michael Hall at the Biozentrum of the University of Basel has also reported that specific cancer cells respond to this combination of drugs. The results of the study have now been published in ‘Science Advances'.
Medicine/Pharmacology - Environment/Sustainable Development
23.12.2016
Fighting cholera by predicting how its spreads
Fighting cholera by predicting how its spreads
In October, EPFL and Médecins Sans Frontières joined forces in an unprecedented effort to predict how the cholera epidemic in Haiti will spread.
Psychology - Medicine/Pharmacology
22.12.2016
Helping pays off: People who care for others live longer
Older people who help and support others live longer. These are the findings of a study published in the journal ‘Evolution and Human Behavior', conducted by researchers from the University of Basel, Edith Cowan University, the University of Western Australia, the Humboldt University of Berlin, and the Max Planck Institute for Human Development in Berlin.
Medicine/Pharmacology
22.12.2016
Roche’s emicizumab for haemophilia A meets primary endpoint in phase III study
Roche's emicizumab for haemophilia A meets primary endpoint in phase III study Emicizumab prophylaxis reduced the number of bleeds over time compared to no prophylaxis in people with haemophilia A an
Medicine/Pharmacology - Life Sciences
21.12.2016
Positive Phase III results for Roche’s investigational medicine OCREVUS (ocrelizumab) published in New England Journal of Medicine
Positive Phase III results for Roche's investigational medicine OCREVUS (ocrelizumab) published in New England Journal of Medicine OCREVUS is the first and only investigational medicine to show superior efficacy versus comparators in both relapsing and primary progressive multiple sclerosis in clinical studies OCREVUS demonstrated a favourable safety profile in three large Phase III studies Roche announced today that data from three Phase III st
Medicine/Pharmacology - Business/Economics
20.12.2016
Novartis bolsters ophthalmology pipeline through acquisition of Encore Vision, Inc
Novartis confirms its leadership in ophthalmology by entering a new therapy area. Acquisition of Encore Vision, Inc.
Medicine/Pharmacology - Life Sciences
19.12.2016
Novartis announces exclusive option, collaboration and license agreement with Conatus to develop new oral treatments for chronic liver diseases
Novartis announces exclusive option, collaboration and license agreement with Conatus to develop new oral treatments for chronic liver diseases Novartis to broaden liver portfolio to deliver best-in
Medicine/Pharmacology - Life Sciences
16.12.2016
Novartis drug Votubia recommended by CHMP for EU approval to treat refractory partial-onset seizures in patients with TSC
If approved, Votubia would be the first adjunctive treatment specifically for refractory seizures in children and adults with tuberous sclerosis complex (TSC)   Seizures are the most common TSC-relat
Medicine/Pharmacology - Life Sciences
16.12.2016
Novartis receives positive CHMP recommendation for Ilaris to treat rare diseases in adults and children called Periodic Fever Syndromes
Periodic Fever Syndromes are rare diseases mostly affecting children and cause recurrent and disabling fevers with potentially life-threatening complications   Ilaris (canakinumab) is recommended for
Medicine/Pharmacology - Business/Economics
16.12.2016
Novartis bolsters innovative dermatology portfolio through acquisition of Ziarco Group Limited
Acquisition to add a once-daily oral H 4 receptor antagonist, ZPL389, to treat atopic dermatitis, commonly known as eczema, to the Novartis industry-leading pipeline    Investigational ZPL389 showed a clinically and statistically significant improvement of eczema lesions, leading to a 50% reduction in EASI score compared to placebo after eight weeks of treatment with a favorable safety profile   Eczema is a chronic, inflammatory skin condition a
Medicine/Pharmacology - Life Sciences
15.12.2016
Magnetic forces purify the blood
Magnetic forces purify the blood
Every five seconds, someone in the world dies from blood poisoning. Hemotune, a young start-up founded by ETH researchers, is developing a revolutionary blood purification system to address this problem. Lukas Langenegger picks up a small glass ampoule containing a dark, reddish-brown fluid. Then he holds a magnet against the vial, and iron particles accumulate on the edge of the glass as if by magic, leaving behind a crystal-clear fluid.
Medicine/Pharmacology
12.12.2016
Novartis provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-related macular degeneration (nAMD or wet AMD)
Novartis provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-related macular degeneration (nAMD or wet AMD) Two pivotal Phase III studies did not show additional improvement in best corrected visual acuity (BCVA) for pegpleranib and Lucentis (ranibizumab) combination treatment over standard of care Lucentis monotherapy , Recent Lucentis EU approval in new choroidal neovascularization (CNV)  indication
Medicine/Pharmacology - Administration/Government
12.12.2016
Novartis launches SMS for Life 2.0 in Nigeria to help improve access to essential medicines
SMS for Life 2.0 launches for the first time in Kaduna State, Nigeria's third most populous region, in collaboration with the Kaduna State Ministry of Health   Program uses smartphones and tablet
Medicine/Pharmacology
12.12.2016
EPFL spinoff QGel raises 12 million dollars from private investors
EPFL spinoff QGel raises 12 million dollars from private investors
QGel is a startup that makes a synthetic gel for growing cells as if they were in the human body. This breakthrough enhances the reliability of research into anti-cancer drugs.
Medicine/Pharmacology
09.12.2016
Novartis LEE011 (ribociclib) plus letrozole analyses show superior PFS across broad spectrum of patients in first-line HR+/HER2- advanced breast cancer versus letrozole
Novartis LEE011 (ribociclib) plus letrozole analyses show superior PFS across broad spectrum of patients in first-line HR+/HER2- advanced breast cancer versus letrozole MONALEESA-2 analyses demonstrate superior PFS with LEE011 plus letrozole in pre-defined patient subgroups - from de novo to bone, liver and lung metastases - compared to letrozole alone   LEE011 plus letrozole reduced risk of progression or death by 55% over letrozole alone in de
Medicine/Pharmacology - Event
08.12.2016
The R. Geigy Foundation honours efforts to overcome ’neglected tropical diseases
Giovanna Raso and Jean Coulibaly are the awardees of the R. Geigy-Award 2016 and will share a CHF 20,000 prize in honour of their efforts to fight neglected helminth infections in West Africa.
Medicine/Pharmacology
08.12.2016
Back to life
«A few months after the proton treatment was over, I realised that I could see more and more. Just dimly, it's true, but I could see! That was sensational!» More than a year ago, Gabi Meier* was treated with proton therapy at the Paul Scherrer Institute PSI.
Medicine/Pharmacology
08.12.2016
Novartis’ Ultibro Breezhaler improved lung function and COPD symptoms after direct switch from previous treatment
Ultibro Breezhaler improved lung function and breathlessness after direct switch from long-acting bronchodilators or steroid-containing combination therapies   Results further support the 2017 GOLD recommendations that dual bronchodilation should be the foundation treatment for the majority of symptomatic COPD patients   Data from the pragmatic CRYSTAL study showcased for the first time at the 2016 British Thoracic Society Winter Meeting in Lond
Medicine/Pharmacology - Life Sciences
07.12.2016
Roche’s Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensitive recurrent ovarian cancer
Roche's Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensitive recurrent ovarian cancer Approval based on two large Phase III studies including GOG-0213 that showed a five month overall survival difference for women with platinum-sensitive recurrent ovarian cancer on Avastin plus chemotherapy compared to chemotherapy alone In the United States, Avastin is now approved for nine distinct uses across six different types of cancer - Roche today announced that the U.S.
Medicine/Pharmacology - Life Sciences
07.12.2016
Novartis’ Lucentis received EU approval in new indication - Lucentis the only treatment available for a wide range of CNV conditions
Novartis' Lucentis received EU approval in new indication - Lucentis the only treatment available for a wide range of CNV conditions The European Commission approved Lucentis to treat patients for vi
Medicine/Pharmacology
07.12.2016
Virtual Reality in Medicine: New Opportunities for Diagnostics and Surgical Planning
Virtual Reality in Medicine: New Opportunities for Diagnostics and Surgical Planning
Before an operation, surgeons have to obtain the most precise image possible of the anatomical structures of the part of the body undergoing surgery.
Environment/Sustainable Development - Medicine/Pharmacology
06.12.2016
Phase two of EPFL's expansion in Valais
Phase two of EPFL's expansion in Valais
Patrick Aebischer and Valais State Councilor Esther Waeber-Kalbermatten signing the agreement, in presence of Martin Vetterli and Jean-Michel Cina.
Medicine/Pharmacology - Life Sciences
06.12.2016
Novartis announces Zykadia first-line study results showing 16.6 month progression-free survival in patients with ALK+ advanced NSCLC
Patients without brain metastases at diagnosis experienced median progression-free survival of 26.3 months, the longest seen in a global Phase III study in ALK+ NSCLC   Patients with measurable brain metastases in the Zykadia arm experienced an intracranial response rate of more than 70%   Data will be used to support global regulatory submissions for first-line use of Zykadia in ALK+ advanced NSCLC patients - Novartis today announced result
Medicine/Pharmacology - Life Sciences
05.12.2016
New interim data demonstrate Sandoz proposed biosimilar rituximab has equivalent efficacy to reference product
ASSIST-FL trial demonstrates equivalent safety, efficacy, pharmacokinetics and pharmacodynamics of Sandoz proposed biosimilar rituximab (GP2013) to the reference product Interim data in over 600 adults show potential of GP2013 as an alternative rituximab Sandoz proposed biosimilar rituximab is the company's first monoclonal antibody candidate Holzkirchen, December 5, 2016 - Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced data from the ASSIST-FL trial.
Medicine/Pharmacology
05.12.2016
Novartis survey uncovers real-world burden of myeloproliferative neoplasms (rare blood cancers) on daily activity and ability to work
Findings across six countries and four continents showed a reduction in quality of life for majority (71%) of patients living with myeloproliferative neoplasms (MPNs)     Patients reported a diminished capacity of more than 35% when trying to work, highlighting reduction in quality of life can extend to the workplace   First international survey of 699 patients with an MPN, specifically myelofibrosis, polycythemia vera or essential thrombocythem
Medicine/Pharmacology - Chemistry
05.12.2016
Novartis data shows Treatment-free Remission rates are consistently above 50% regardless of reason for switch to Tasigna from Glivec
ENESTop post-hoc analysis provides further insights into Treatment-free Remission (TFR) among Ph+ CML switch patients The Tasigna TFR trials, including ENESTop, demonstrate our continued commitment to the CML community - Novartis today announced at the 58th American Society of Hematology (ASH) Annual Meeting & Exposition new data from the Tasigna (nilotinib) ENESTop Treatment-free Remission (TFR) study, which demonstrate that TFR rates are c
Medicine/Pharmacology - Life Sciences
05.12.2016
Re-emergence of Syphilis Traced to Pandemic Strain Cluster
Re-emergence of Syphilis Traced to Pandemic Strain Cluster
Syphilis has plagued humankind for over 500 years. After the first reported outbreaks struck Europe in 1495, the disease spread rapidly to other continents and swelled to a global pandemic. When treatment with the antibiotic penicillin became available in the mid-twentieth century, infection rates started to decrease dramatically.
Life Sciences - Medicine/Pharmacology
05.12.2016
Researchers uncover protein-based ‘cancer signature'
Researchers uncover protein-based ‘cancer signature’
A research team at the University of Basel's Biozentrum has investigated the expression of ribosomal proteins in a wide range of human tissues including tumors and discovered a cancer type specific signature. As the researchers report in ‘Genome Biology' this ‘cancer signature' could potentially be used to predict the progression of the disease.
Medicine/Pharmacology - Physics/Materials Science
05.12.2016
Roche’s Gazyva/Gazyvaro Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared to MabThera/Rituxan
Roche's Gazyva/Gazyvaro Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared to MabThera/Rituxan First Phase III study to show superior progression-free survival compared to MabThera/Rituxan-based standard of care treatment for most common slow-growing form of non-Hodgkin lymphoma Results were presented during the Plenary Scientific Session at 58th American Society of Hema
Medicine/Pharmacology - Life Sciences
04.12.2016
Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL
82% (41 of 50) of patients achieved complete remission or complete remission with incomplete blood count recovery in interim analysis of Novartis study (ELIANA) ELIANA, the first global CAR T'cell tr
Medicine/Pharmacology
03.12.2016
Novartis SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequency of sickle cell pain crises in Phase II study
SEG101 reduced annual rate of sickle cell-related pain crises (SCPC) by 45.3% compared to placebo in patients with or without hydroxyurea therapy   SEG101 is a potential new disease-modifying, preventive treatment option for patients with SCPC; first in nearly 20 years   Data being highlighted in ASH 2016 media briefing, presented at Plenary Scientific Session and published simultaneously in The New England Journal of Medicine Basel, Decembe
Medicine/Pharmacology
30.11.2016
World Aids Day 2016: Hands Up for #HIVprevention
Over the past 35 years the global impact of HIV has changed the course of history. In spite of progress in access to testing and treatment in the last decade, inadequate investment in prevention means that some of the most vulnerable people remain at risk.
Medicine/Pharmacology - Business/Economics
29.11.2016
Novartis Access shares one-year learnings and announces memorandum of understanding with Rwanda
Rwanda becomes third country to launch Novartis Access portfolio against chronic diseases with first deliveries planned in early 2017 Since September 2015, Novartis Access has delivered more than 100
Medicine/Pharmacology - Life Sciences
28.11.2016
Successfully Treating Genetically Determined Autoimmune Enteritis
Using targeted immunotherapy, doctors have succeeded in curing a type of autoimmune enteritis caused by a recently discovered genetic mutation. This report comes from researchers at the Department of Biomedicine of the University of Basel and University Hospital Basel. Their results raise new possibilities for the management of diarrhea, which is often a side effect of melanoma treatment.
Medicine/Pharmacology - Physics/Materials Science
25.11.2016
20 years of high-precision combat against cancer
20 years of high-precision combat against cancer
Developed at the Paul Scherrer Institute PSI, the spot-scanning technique for proton therapy has been treating patients, gently and efficiently, since 1996. At the Paul Scherrer Institute PSI on the 25th of November, 1996, the first cancer patient worldwide was treated with a new irradiation method: the so-called spot-scanning technique for proton beams.
Medicine/Pharmacology - Physics/Materials Science
24.11.2016
Depression in Young People Affects the Stomach, Anxiety the Skin
Mental disorders and physical diseases frequently go hand in hand. For the first time, psychologists at the University of Basel and Ruhr University Bochum have identified temporal patterns in young people: arthritis and diseases of the digestive system are more common after depression, while anxiety disorders tend to be followed by skin diseases.
Medicine/Pharmacology - Agronomy/Food Science
22.11.2016
Food data at your fingertips
Food data at your fingertips
EPFL is launching openfood.ch, a website that provides the public with data on more than 14,000 food products sold in Switzerland.
Medicine/Pharmacology
21.11.2016
Novartis commends publication of major report which recommends broad use of dual bronchodilators to treat COPD
2017 GOLD report recommends the first-line use of dual bronchodilators, such as Ultibro Breezhaler , in the treatment of the majority of symptomatic COPD patients   Bronchodilation regarded as the fo
Medicine/Pharmacology - Business/Economics
21.11.2016
Novartis acquires Selexys Pharmaceuticals Corporation and SelG1 antibody for reduction of pain crises in sickle cell disease (SCD)
Deal followed results of Phase II SUSTAIN study of SelG1 in reduction of vaso-occlusive pain crises, a major complication of SCD with limited treatment options   Results of SUSTAIN will be presented
Medicine/Pharmacology - Life Sciences
18.11.2016
Innovative study with three treatment switches confirms Sandoz biosimilar etanercept has equivalent efficacy to originator
No clinically meaningful differences between biosimilar etanercept and the originator product in safety and efficacy over 52 weeks   Innovative study design demonstrates switching between biosimilar etanercept and the originator product has no impact on safety and efficacy   Sandoz biosimilar etanercept was approved by the FDA* in August 2016 and is currently under review by the EMA ** Holzkirchen, November 18, 2016 - Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced the publication of the EGALITY study in the British Journal of Dermatology .
Medicine/Pharmacology - Life Sciences
17.11.2016
Antibiotic resistance: Swiss physicians, vets, biologists and environmental researchers are working together to find solutions
Antibiotic resistance: Swiss physicians, vets, biologists and environmental researchers are working together to find solutions
The SNSF is launching the National Research Programme "Antimicrobial Resistance", which aims to develop new solutions to ensure that antibiotics remain effective. Worldwide, more and more pathogens are becoming resistant to today's antibiotics. The aim of European Antibiotic Awareness Day on 18 November 2016 is to highlight the fact that medicines are losing their effectiveness as a result and that once easy-to-treat infections are turning into deadly diseases.
1 2 3 4 5 ... 21 Next »